Registry for adults with UTUC treated with Jelmyto
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Have a diagnosis of UTUC (upper tract urothelial cancer)
- Have received at least one dose of Jelmyto after April 15, 2020
- Be able to give informed consent
- Not be pregnant or breastfeeding
- Be able and willing to follow the study’s check-ins and data collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
This program provides access to a chemotherapy drug called mitomycin, given as a liquid into the kidney area, for people with a certain type of cancer in the upper urinary tract. It aims to see if this treatment can help when standard options are not suitable.
This is a study that looks back at past medical records of adults with metastatic urinary tract cancer. It specifically includes people who received certain immunotherapy or antibody-drug treatments during set time periods, to help researchers understand outcomes and care patterns.
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
This trial tests whether giving a chemotherapy drug called mitomycin C directly into the bladder after a ureteroscopy can help prevent upper tract urothelial cancer from coming back or spreading. It is for people who are newly suspected of having this cancer and are about to have a diagnostic ureteroscopy.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.